Aziyo Biologics Inc. (AZYO): Price and Financial Metrics
GET POWR RATINGS... FREE!
AZYO Stock Summary
- AZYO has a market capitalization of $73,216,181 -- more than approximately only 12.26% of US stocks.
- Aziyo Biologics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 86.75% of US listed stocks.
- AZYO's went public 1.47 years ago, making it older than merely 2.48% of listed US stocks we're tracking.
- Stocks that are quantitatively similar to AZYO, based on their financial statements, market capitalization, and price volatility, are BDSX, RDHL, PRTK, HTGM, and SNES.
- AZYO's SEC filings can be seen here. And to visit Aziyo Biologics Inc's official web site, go to www.aziyobiologics.com.
AZYO Valuation Summary
- AZYO's EV/EBIT ratio is -7.1; this is 124.23% lower than that of the median Healthcare stock.
- Over the past 47 weeks, AZYO's price/sales ratio has gone down 1.9.
- Over the past 47 weeks, AZYO's price/sales ratio has gone down 1.9.
Below are key valuation metrics over time for AZYO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AZYO | 2021-08-31 | 1.7 | 5.6 | -3.7 | -7.1 |
| AZYO | 2021-08-30 | 1.7 | 5.6 | -3.6 | -7.1 |
| AZYO | 2021-08-27 | 1.7 | 5.5 | -3.6 | -7.0 |
| AZYO | 2021-08-26 | 1.7 | 5.7 | -3.7 | -7.2 |
| AZYO | 2021-08-25 | 1.7 | 5.5 | -3.6 | -7.0 |
| AZYO | 2021-08-24 | 1.7 | 5.6 | -3.6 | -7.1 |
AZYO Price Target
For more insight on analysts targets of AZYO, see our AZYO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $16.50 | Average Broker Recommendation | 1.5 (Moderate Buy) |
AZYO Stock Price Chart Interactive Chart >
AZYO Price/Volume Stats
| Current price | $6.72 | 52-week high | $10.55 |
| Prev. close | $7.00 | 52-week low | $4.10 |
| Day low | $6.45 | Volume | 26,442 |
| Day high | $7.17 | Avg. volume | 9,662 |
| 50-day MA | $6.45 | Dividend yield | N/A |
| 200-day MA | $6.23 | Market Cap | 91.12M |
Aziyo Biologics Inc. (AZYO) Company Bio
Aziyo Biologics, Inc. operates as a biotechnology company which focuses on regenerative medicine in areas such as cardiology, orthopedics and other medical specialties. It offers cardiac device envelope, vascular surgery, cardiothoracic repair, orthopedics and spine, sports medicine, dermal, and wound care. The company was founded on August 6, 2015 and is headquartered in Silver Spring, MD.
Latest AZYO News From Around the Web
Below are the latest news stories about Aziyo Biologics Inc that investors may wish to consider to help them evaluate AZYO as an investment opportunity.
Aziyo Biologics to Participate in the Cowen 42nd Annual Health Care ConferenceSILVER SPRING, Md., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming 42nd Annual Cowen Health Care Conference. Date: Wednesday, March 9, 2022Format: Fireside chat and 1x1 meetings The fireside chat will be hosted at 12:50 p.m. ET. A live and arc |
Aziyo Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 3, 2022SILVER SPRING, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its fourth quarter and full year 2021 earnings results after market close on Thursday, March 3, 2022. Management will host a conference call to review the Company’s financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast. |
All You Need to Know About Aziyo Biologics, Inc. (AZYO) Rating Upgrade to BuyAziyo Biologics, Inc. (AZYO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Has Aziyo Biologics, Inc. (AZYO) Outpaced Other Medical Stocks This Year?Here is how Aziyo Biologics, Inc. (AZYO) and Doximity (DOCS) have performed compared to their sector so far this year. |
Stonegate Capital Partners Initiates Coverage on Aziyo Biologics, Inc. (NASDAQ:AZYO)DALLAS, TX / ACCESSWIRE / January 18, 2022 / Aziyo Biologics, Inc. (NASDAQ:AZYO): The full report can be accessed by clicking on the following link: http://stonegateinc. |
AZYO Price Returns
| 1-mo | 6.84% |
| 3-mo | 17.38% |
| 6-mo | 7.01% |
| 1-year | -36.36% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 6.67% |
| 2021 | -53.78% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...